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There is a current lack of consensus regarding methods of assessment of vitiligo. Recently, the Vitiligo Area Scoring Index (VASI)
and the Vitiligo European Task Force (VETF) were proposed to oﬀer more accurate measures of disease severity indexes and
treatment evaluation criteria. It would make sense to combine the VASI with the VETF system. We proposed an original scale for
treatment evaluation criteria in vitiligo based on VASI. We plan to add the digital image analysis system, health-related quality of
life questionnaire, aﬀected skin location, and skin color in the originalscale.
1.Introduction
Vitiligo, the most common depigmenting disorder, aﬀects
0.5–1% of the worldwide population, causing disﬁgurement
and serious disturbances in quality of life. There is a
current lack of consensus on methods of assessment of this
disorder, which makes it generally impossible to perform
meta-analyses or compare the outcomes of diﬀerent studies
of the same treatment or parameter. Recently, the Vitiligo
Area Scoring Index (VASI) [1] and the Vitiligo European
Task Force (VETF) [2] tools were proposed to oﬀer more
accurate measures of disease severity indexes and treatment
evaluation criteria compared to simple clinical photography
alone. VASI provides a relatively simple method, analogous
to the Psoriasis Area Severity Index (PASI), to measure
repigmentation. Using tools developed by VETF vitiligo and
treatment outcomes can be assessed using a system that
combines analysis of extent and stage of disease and disease
progression [3]. Extent is evaluated by the rule of nines,
staging is based on cutaneous and hair pigmentation, and
spreading is assessed based on Wood’s light examination.
2.VitiligoArea ScoringIndex(VASI)
Hamzavi et al. [1] have introduced a quantitative parametric
score, named VASI for Vitiligo Area Scoring Index, which
is conceptually derived from the PASI score widely used in
psoriasis assessment [3]. The total body VASI is calculated
using a formula that includes contributions from all body
regions (possible range, 0–100)
VASI
=

All Body Sites
[Hand Units] ×

Residual Depigmentation

.
(1)
One hand unit, which encompasses the palm plus the volar
surface of all the digits, is approximately 1% of the total
body surface area [4] and is used as a guide to estimate
the baseline percentage of vitiligo involvement in each body
region. The body is divided into ﬁve separate and mutu-
ally exclusive regions: hands, upper extremities (excluding
hands), trunk, lower extremities (excluding feet), and feet.2 Dermatology Research and Practice
The axillary region is included with the upper extremities
while the buttocks and inguinal areas are included with the
lower extremities. The extent of residual depigmentation is
expressed by the following percentages: 0, 10%, 25%, 50%,
75%, 90%, or 100%. At 100% depigmentation, no pigment
is present; at 90%, specks of pigment are present; at 75%,
the depigmented area exceeds the pigmented area; at 50%,
the depigmented and pigmented areas are equal; at 25%, the
pigmented area exceeds the depigmented area; at 10%, only
specks of depigmentation are present.
3.VitiligoEuropeanTaskForce(VETF)
The VETF proposed a system that combines analysis of
extent, stage of disease (staging), and disease progression
(spreading) [2]. Extent is evaluated using the rule of nines
[5], already used in atopic dermatitis assessment [6]. Staging
is based on cutaneous and hair pigmentation in vitiligo
patches,and thedisease isstaged0–3onthelargest maculein
each body region, except hands and feet, which are assessed
separately and globally as one unique area.
A proposal was made for simplifying the staging scale:
stage 0: normal pigmentation (no depigmentation in
area graded),
stage1:incompletedepigmentation(includingspotty
depigmentation, trichrome, and homogeneous
lighter pigmentation)
stage 2: complete depigmentation (may include hair
whitening in a minority of hairs, <30%),
stage 3: complete depigmentation plus signiﬁcant
hair whitening (>30%).
“Spreading” in VETF was introduced to include a dynamic
dimension, since rapidly progressive vitiligo needs urgent
interventiontostabilizethedisease.Theproposedgridallows
scoring this dimension on a simple scale (+1: progressive; 0:
stable; −1: regressive). Spreading is assessed by combining
Wood’s lamp and electric light examinations in a dark room.
Wood’s lamp includes a magnifying lens to assess hairs,
especially vellus hairs.
4.Discussion
It is diﬃcult to compare the eﬃcacy of diﬀerent treat-
ment modalities in vitiligo [7]. Based on the currently
available literature, it would make sense to combine the
depigmentation scale of VASI with the VETF system. The
VETF system cannot always be easily handled in clinical
practice because Wood’s lamp examination is troublesome.
In addition, Wood’s lamp may not be popular in non-
Europeancountries. The improvement ofvitiligo fortherapy
is more slowly compared to that of psoriasis in general.
We suggest that a 50% reduction in VASI score (VASI 50)
equates a clinical improvement of a 75% reduction in PASI
score (PASI 75). Therefore, we propose an original scale for
treatment evaluationcriteria in vitiligo as follows: very much
improved (increased more than 50 points of VASI score),
Table 1
VASI score ∼−50 Very much worse
VASI score −50∼−25 Much worse
VASI score −25∼−10 Worse
VASI score −10 ∼ 0 Minimally worse
VASI score 0 ∼+10 Minimally improved
VASI score +10 ∼25 Improved
VASI score +25 ∼50 Much improved
VASI score +50∼ Very much improved
much improved (25–50 points increase of VASI score),
improved (10–25 points increase of VASI score), minimally
improved (less than 10 points increase of VASI score). In
contrast, very much worse (decreased more than 50 points
of VASI score), much worse (25–50 points decrease of VASI
score), worse (10–25 points decrease of VASI score), and
minimally worse (less than 10 points decrease of VASI score)
(Table 1). A new digital image analysis system (DIAS) for
the surface measurement of vitiligo lesions was proposed
[8]. Extending the system to include 3D information would
probablyallow much largerareas to be measured reliably. We
may adopt the DIAS for treatment evaluation in vitiligo.
An important aspect of the therapeutic response is how
the patients feel about their vitiligo after the treatment
because there is a psychological point of view to the disease.
Vitiligo is often immediately visible to others, and those with
the condition may suﬀer social and emotional consequences
including low self-esteem, social anxiety, depression, stigma-
tization, and, in extreme cases, rejection by those around
them [9]. Assessment of treatment eﬃcacy should include
quality of life with regard to the psychological eﬀects. One
way of evaluating the burden of vitiligo is by measuring
the health-related quality of life (HRQL) using standardized
questionnaires to measure the impact of a disease on the
physical, psychologic, and social functioning, and the well-
being of the patient [5]. We will add dermatology-speciﬁc
HRQL questionnaire such as Skindex and Dermatology Life
Quality Index in our original scale.
The Pemphigus Disease Area Index (PDAI) has twofold
higher score for oral involvement compared to skin involve-
ment [10]. Depigmentation on the face and neck seems to
be psychologically more harmful than that on trunk and
extremities. Severity Indexes of vitiligo on the face and neck
should receive twofold higher scoring than that on the rest
of the body in analogy with the PDAI. In addition, skin
color (skin types I to VI according to Fitzpatrick) should
be assessed separately in the disease severity indexes and
treatment evaluation criteria. In people with a pale white
skin color (skin type I–III), vitiligo may cause little concern.
In contrast, yellow and black people with dark skin (skin
type IV–VI) may be anxious about depigmentation. Some
additional clinical studies would be required to adequately
address aﬀected skin location and skin color in disease
severity indexes and treatment evaluation criteria of vitiligo.Dermatology Research and Practice 3
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